Analytical Data
-
Gene name
GFAP
- Application
-
Alternative Names
GFAP；Glial fibrillary acidic Protein
-
Species
Human
-
Source
E. coli
-
Tag
N-6His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P14136
-
Expression Region
1-432aa
-
AA Sequence
MERRRITSAARRSYVSSGEMMVGGLAPGRRLGPGTRLSLARMPPPLPTRVDFSLAGALNAGFKETRASERAEMMELNDRFASYIEKVRFLEQQNKALAAELNQLRAKEPTKLADVYQAELRELRLRLDQLTANSARLEVERDNLAQDLATVRQKLQDETNLRLEAENNLAAYRQEADEATLARLDLERKIESLEEEIRFLRKIHEEEVRELQEQLARQQVHVELDVAKPDLTAALKEIRTQYEAMASSNMHEAEEWYRSKFADLTDAAARNAELLRQAKHEANDYRRQLQSLTCDLESLRGTNESLERQMREQEERHVREAASYQEALARLEEEGQSLKDEMARHLQEYQDLLNVKLALDIEIATYRKLLEGEENRITIPVQTFSNLQIRETSLDTKSVSEGHLKRNIVVKTVEMRDGEVIKESKQEHKDVM
-
Molecular Weight
55 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Identification
Protein Description
Glial fibrillary acidic protein (GFAP) is a key intermediate filament protein predominantly expressed in astrocytes, playing a crucial role in maintaining the structural integrity and function of the central nervous system. Research into recombinant GFAP has gained significant attention due to its involvement in various neurological disorders, including Alzheimer's disease, multiple sclerosis, and traumatic brain injury. The study of GFAP is pivotal for understanding gliosis, a reactive process characterized by astrocyte proliferation and altered GFAP expression in response to CNS injury. By developing recombinant GFAP, researchers can investigate its structural properties, signaling pathways, and interactions with other proteins in a controlled environment, thereby gaining insights into astrocyte behavior under pathological conditions. Additionally, the production of GFAP as a recombinant protein facilitates the creation of diagnostic tools and therapeutic strategies, allowing for the exploration of GFAP as a biomarker for neuroinflammation and glial activation. This burgeoning field of study not only enhances our comprehension of astrocyte biology but also opens avenues for novel interventions in neurodegenerative diseases, making GFAP a focal point in both basic and translational neuroscience research.
